Vietnam Cryptococcal Retention in Care Study (CRICS) Federal Financial Report

PHASE1CompletedINTERVENTIONAL
Enrollment

1,177

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions
Cryptococcal Meningitis
Interventions
OTHER

Vietnam Cryptococcal Retention in Care Study (CRICS)

"Drug: Fluconazole HIV-infected patients with CD4 ≤100 cells/μL who present for HIV care at outpatient clinics (OPCs) in Vietnam where CrAg screening is offered will be recruited into the study. Study participants will be screened for cryptococcal antigen using the Lateral Flow Assay (LFA). Those who are CrAg-positive, but have no features of central nervous system (CNS) disease, will be treated with high-dose fluconazole.~Other Names:~• Fluconazole"

Trial Locations (1)

Unknown

National hospital for tropical diseases, Ham Zong

All Listed Sponsors
lead

National Hospital for Tropical Diseases, Hanoi, Vietnam

OTHER_GOV

NCT02955862 - Vietnam Cryptococcal Retention in Care Study (CRICS) Federal Financial Report | Biotech Hunter | Biotech Hunter